Journal
EUROPEAN NEUROLOGY
Volume 72, Issue -, Pages 12-14Publisher
KARGER
DOI: 10.1159/000367618
Keywords
Driving ability; Observational studies; Patient registries; Safety; Spasticity; THC:CBD oromucosal spray
Categories
Funding
- Laboratorios Almirall SA (Barcelona, Spain)
Ask authors/readers for more resources
Background:Clinical trials demonstrate the efficacy and tolerability of an intervention under experimental conditions, but information on use under daily practice conditions is required to confirm the effectiveness and safety of new management options. Summary:Clinical outcomes for THC:CBD oromucosal spray (Sativex (R)) in patients with treatment-resistant MS spasticity have been collected in post-marketing safety registries from the UK and Germany, a safety study from Spain and two observational studies from Germany, including one investigating its effects on driving ability. Collectively, findings from daily practice support the long-term effectiveness and safety of THC:CBD oromucosal spray. The proportion of patients with a clinically relevant response (>= 30% improvement from baseline on the spasticity 0-10 Numerical Rating Scale) at 3 months was similar to that reported in a large enriched-design pivotal clinical trial (41 vs. 36%). There was no evidence of abuse/misuse or other adverse events of special interest with a cannabis-based medicine and no impairment of driving ability. In actual clinical practice, average daily doses were similar to 25% lower than those used in clinical trials. Key Messages: Observational data and real world experience reinforce the efficacy and safety of THC:CBD oromucosal spray as reported in phase III clinical trials. (c) 2014 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available